Emcure Pharma incorporates new wholly-owned subsidiary Emcure Wellness
Pune: Emcure Pharmaceuticals Limited has announced the incorporation of a new wholly-owned subsidiary named Emcure Wellness Private Limited.
The new entity was officially incorporated on July 3, 2025, in Pune, Maharashtra, following necessary regulatory approvals, the company disclosed in a filing to the stock exchanges.
This development follows Emcure’s earlier announcement in June, wherein the Board of Directors had approved the proposal to set up a subsidiary to manufacture, promote, sell, and distribute pharmaceutical and related products.
As per the details shared, the proposed authorized share capital of Emcure Wellness Private Limited stands at Rs 10 crore, while the proposed paid-up share capital is Rs 1 lakh.
In a related move, Medical Dialogues team earlier reported in June that Emcure Pharma had also received board approval to enter into agreement with minority shareholders of Zuventus Healthcare Ltd., one of its subsidiaries, to acquire their shareholding. Following the completion of this transaction, Zuventus will become a wholly owned subsidiary of Emcure.
Read also: Emcure Pharma to acquire remaining stake in arm Zuventus Healthcare
Additionally, in April 2025, Tillomed Laboratories Limited, a subsidiary of Emcure Pharma and a European pharma company, entered into an Asset Purchase Agreement (APA) with UK based Manx Healthcare Limited and its subsidiaries Manx Pharma Ltd and Manx Generics Limited.
Established in 1981, Emcure Pharmaceuticals Ltd. is an Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Emcure is present in 70+ countries globally including Europe and Canada.
